Literature DB >> 15193913

RNA interference as a new strategy against viral hepatitis.

Senthil K Radhakrishnan1, Thomas J Layden, Andrei L Gartel.   

Abstract

Hepatitis viruses are the leading cause of liver cirrhosis and hepatocellular carcinoma worldwide. Since currently available treatment options against these viruses are limited, there is a need for development of alternative therapies. In this minireview, we concentrate on three hepatitis viruses--hepatitis C virus, hepatitis B virus, and hepatitis delta virus and discuss how RNA interference (RNAi) has been utilized against them. RNAi is a process by which small double-stranded RNA can effectively target a homologous RNA sequence for degradation by cellular ribonucleases. Though RNAi was exploited in the beginning for down-regulating cellular genes, it has recently been demonstrated that this process is equally effective against many types of human and animal viruses including the hepatitis viruses. Both synthetic small-interfering RNAs (siRNAs) and plasmid-based siRNA expression systems have been useful in suppressing the hepatitis viruses. Though this new approach looks promising, problems of nonspecific effects and delivery may need to be addressed before the full therapeutic potential of RNAi against viral infections in patients is realized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193913     DOI: 10.1016/j.virol.2004.02.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  19 in total

1.  Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape.

Authors:  Joshua N Leonard; David V Schaffer
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

2.  Inorganic nanovectors for nucleic acid delivery.

Authors:  Sandhya Pranatharthiharan; Mitesh D Patel; Anisha A D'Souza; Padma V Devarajan
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

Review 3.  Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.

Authors:  Jason Lamontagne; Laura F Steel; Michael J Bouchard
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 4.  Hepatitis C virus infection--pathobiology and implications for new therapeutic options.

Authors:  Gary L Davis; Kris Krawczynski; Gyongyi Szabo
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

5.  Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs.

Authors:  Susan L Uprichard; Bryan Boyd; Alana Althage; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-07       Impact factor: 11.205

6.  Inhibition of hepatitis B virus gene expression and replication by artificial microRNA.

Authors:  Yu-Feng Gao; Li Yu; Wei Wei; Jia-Bin Li; Qing-Li Luo; Ji-Long Shen
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

7.  Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts.

Authors:  Lindsey L Snyder; Jonathan M Esser; Catherine J Pachuk; Laura F Steel
Journal:  Antiviral Res       Date:  2008-05-06       Impact factor: 5.970

8.  Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90.

Authors:  Ana Claudia Silva Braga; Bruno Moreira Carneiro; Mariana Nogueira Batista; Mônica Mayumi Akinaga; Paula Rahal
Journal:  Cell Stress Chaperones       Date:  2016-11-17       Impact factor: 3.667

9.  RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells.

Authors:  Mohammed Abdelfatah Alhoot; Seok Mui Wang; Shamala Devi Sekaran
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

10.  Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA.

Authors:  Lei Deng; Guoqiang Li; Lisen Xi; Aihong Yin; Yun Gao; Wei You; Xuehao Wang; Beicheng Sun
Journal:  BMC Gastroenterol       Date:  2009-10-06       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.